验证数据展示
经过测试的应用
Positive IF/ICC detected in | HeLa cells |
推荐稀释比
Application | Dilution |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL594-67843 targets CIP2A in IF/ICC applications and shows reactivity with Human, rat samples.
Tested Applications | IF/ICC Application Description |
Tested Reactivity | Human, rat |
Immunogen | CIP2A fusion protein Ag19598 种属同源性预测 |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Full Name | KIAA1524 |
Synonyms | Cancerous inhibitor of PP2A, CIP2A, FLJ12850, KIAA1524, p90, p90 autoantigen, Protein CIP2A |
Calculated Molecular Weight | 905 aa, 102 kDa |
Observed Molecular Weight | 102 kDa |
GenBank Accession Number | BC130564 |
Gene Symbol | CIP2A |
Gene ID (NCBI) | 57650 |
RRID | AB_2934781 |
Conjugate | CoraLite®594 Fluorescent Dye |
Excitation/Emission Maxima Wavelengths | 588 nm / 604 nm |
Form | Liquid |
Purification Method | Protein G purification |
UNIPROT ID | Q8TCG1 |
Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
Cancerous inhibitor of protein phosphatase 2A (CIP2A) was originally identified as a cellular protein phosphatase 2A (PP2A) inhibitor, and has been shown to control oncogenic cellular signals by suppressing the tumor suppressor PP2A. CIP2A overexpression has been found in several human malignancies including breast cancer, hepatocellular carcinoma, gastric cancer, head and neck cancer, colon cancer, prostate cancer and non-small cell lung cancer. CIP2A is a 83~102 kDa cytoplasmic protein. ( PMID: 26824320, PMID: 25458953, PMID: 29720672)
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL594 CIP2A antibody CL594-67843 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |